Loading...
•
Mar 31, 2022
scPharmaceuticals Q1 2022 Earnings Report
scPharmaceuticals reported financial results for Q1 2022 and provided a business update.
Key Takeaways
scPharmaceuticals reported a net loss of $7.7 million for the first quarter of 2022. The company ended the quarter with $65.6 million in cash, cash equivalents, restricted cash and investments. The FDA has accepted for review its New Drug Application (NDA) resubmission for FUROSCIX with a target action date of October 8, 2022.
FDA accepted for review the NDA resubmission for FUROSCIX with a PDUFA target action date of October 8, 2022.
Continued to advance commercial readiness activities in anticipation of a Q4 2022 commercial launch of FUROSCIX, if approved.
Ended Q1 2022 with $65.6 million in cash, cash equivalents, restricted cash and investments.
Reported a net loss of $7.7 million for the first quarter of 2022.
Forward Guidance
Based on its current operating plan, the Company reiterates its 2022 forecast and expects net loss to be $43 to $48 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...